GERN
Price
$1.48
Change
-$0.05 (-3.27%)
Updated
Jun 27 closing price
Capitalization
942.64M
39 days until earnings call
SER
Price
$6.17
Change
+$0.04 (+0.65%)
Updated
Jun 27 closing price
Capitalization
61.5M
Interact to see
Advertisement

GERN vs SER

Header iconGERN vs SER Comparison
Open Charts GERN vs SERBanner chart's image
Geron
Price$1.48
Change-$0.05 (-3.27%)
Volume$16.33M
Capitalization942.64M
Serina Therapeutics
Price$6.17
Change+$0.04 (+0.65%)
Volume$15.71K
Capitalization61.5M
GERN vs SER Comparison Chart in %
Loading...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SER
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GERN vs. SER commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Buy and SER is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (GERN: $1.48 vs. SER: $6.17)
Brand notoriety: GERN and SER are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GERN: 155% vs. SER: 127%
Market capitalization -- GERN: $942.64M vs. SER: $61.5M
GERN [@Biotechnology] is valued at $942.64M. SER’s [@Biotechnology] market capitalization is $61.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GERN’s FA Score shows that 0 FA rating(s) are green whileSER’s FA Score has 0 green FA rating(s).

  • GERN’s FA Score: 0 green, 5 red.
  • SER’s FA Score: 0 green, 5 red.
According to our system of comparison, SER is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GERN’s TA Score shows that 4 TA indicator(s) are bullish while SER’s TA Score has 7 bullish TA indicator(s).

  • GERN’s TA Score: 4 bullish, 3 bearish.
  • SER’s TA Score: 7 bullish, 1 bearish.
According to our system of comparison, SER is a better buy in the short-term than GERN.

Price Growth

GERN (@Biotechnology) experienced а -1.99% price change this week, while SER (@Biotechnology) price change was +14.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

GERN is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GERN($943M) has a higher market cap than SER($61.5M). SER YTD gains are higher at: 23.154 vs. GERN (-58.192). SER has higher annual earnings (EBITDA): -488K vs. GERN (-114.49M). GERN has more cash in the bank: 397M vs. SER (4.27M). SER has less debt than GERN: SER (227K) vs GERN (122M). GERN has higher revenues than SER: GERN (116M) vs SER (0).
GERNSERGERN / SER
Capitalization943M61.5M1,533%
EBITDA-114.49M-488K23,461%
Gain YTD-58.19223.154-251%
P/E RatioN/A1.83-
Revenue116M0-
Total Cash397M4.27M9,304%
Total Debt122M227K53,744%
FUNDAMENTALS RATINGS
GERN vs SER: Fundamental Ratings
GERN
SER
OUTLOOK RATING
1..100
2295
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6550
P/E GROWTH RATING
1..100
74100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SER's Valuation (84) in the null industry is in the same range as GERN (93) in the Biotechnology industry. This means that SER’s stock grew similarly to GERN’s over the last 12 months.

SER's Profit vs Risk Rating (100) in the null industry is in the same range as GERN (100) in the Biotechnology industry. This means that SER’s stock grew similarly to GERN’s over the last 12 months.

GERN's SMR Rating (97) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that GERN’s stock grew similarly to SER’s over the last 12 months.

SER's Price Growth Rating (50) in the null industry is in the same range as GERN (65) in the Biotechnology industry. This means that SER’s stock grew similarly to GERN’s over the last 12 months.

GERN's P/E Growth Rating (74) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that GERN’s stock grew similarly to SER’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GERNSER
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 19 days ago
77%
N/A
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
83%
Aroon
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SER
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGJMX125.931.87
+1.51%
Fidelity Advisor Communication ServicesI
UPUPX11.410.09
+0.80%
Upright Growth
TESIX25.900.11
+0.43%
Franklin Mutual Shares A
SCAYX11.460.04
+0.35%
Invesco Income Advantage U.S. Fund Y
RLACX24.020.08
+0.33%
Russell Inv US Small Cap Equity A

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-3.27%
SER - GERN
65%
Loosely correlated
+0.65%
DAWN - GERN
39%
Loosely correlated
-0.15%
XNCR - GERN
36%
Loosely correlated
-3.10%
ATXS - GERN
36%
Loosely correlated
N/A
CCCC - GERN
35%
Loosely correlated
-7.89%
More

SER and

Correlation & Price change

A.I.dvisor indicates that over the last year, SER has been loosely correlated with GERN. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SER jumps, then GERN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SER
1D Price
Change %
SER100%
+0.65%
GERN - SER
65%
Loosely correlated
-3.27%
XTLB - SER
59%
Loosely correlated
N/A
ELVN - SER
37%
Loosely correlated
-3.95%
ENTBF - SER
35%
Loosely correlated
+12.13%
TOVX - SER
34%
Loosely correlated
-2.32%
More